Tirzepatide Shortage Resolved; Compounder Sues FDA; Menopause Mistaken as Dementia

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA’s shortage list. (Reuters)

This prompted a compounding group to sue the FDA for removing the drug from said list. (Reuters)

Meanwhile, the agency clarified its policies on the legal restrictions for making copies of approved drugs for compounders. Certain dosages of the GLP-1 receptor agonists dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy), and liraglutide (Victoza, Saxenda) are still in shortage.

Bothersome menopause symptoms like hot flashes often aren’t being documented in patients’ electronic health records after primary care visits, according to a retrospective review. (Menopause)

Teva Pharmaceuticals announced the launch of the first generic of octreotide acetate for injectable suspension (Sandostatin LAR Depot) for the treatment of acromegaly.

The Endocrine Society is hosting its first-ever Artificial Intelligence in Healthcare Virtual Summit in November, which will explore AI’s potential to revolutionize patient care and shape the future of medicine.

A U.K. woman’s dementia was misdiagnosed as menopause for 2 years. (BBCNews)

Teva Pharmaceuticals’ biosimilar candidate to the osteoporosis drug denosumab (Prolia) is under FDA review, the company said.

In a randomized trial of older women with type 2 diabetes, twice-daily treatment with the vitamin B6 metabolite pyridoxamine for 1 year was linked to increases in the bone formation marker P1NP, bone density at the femoral neck, and a decrease in HbA1c. (Journal of Clinical Endocrinology & Metabolism)

WeightWatchers is adding a compounded version of semaglutide to its weight management program.

NPR spoke with activists arguing for a ban on in vitro fertilization.

The “obesity first” healthcare movement is changing how some clinicians treat chronic conditions. (Washington Post)

Digital voice analysis using broad acoustic analysis and machine learning identified patients with acromegaly more accurately than 12 experienced endocrinologists in a Swedish study. (Journal of Clinical Endocrinology & Metabolism)